Forty Seven's IO Antibody Attracts Two Big Pharma Partners

 
• By Lucie Ellis-Taitt

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

Cancer-cells-pink-color_1200x675
More cancer combinations: Forty Seven to pair lead compound with PD-L1s

More from Immuno-oncology

More from Anticancer